Nalaganje...

Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy

Crizotinib is a multi-targeted tyrosine kinase inhibitor (TKI) with activity against mesenchymal-epithelial transition factor (MET) and anaplastic lymphoma kinase (ALK). However, the concomitant oncogenic drivers may affect the sensitivity of crizotinib. Herein, we present a 69-year-old never-smoker...

Popoln opis

Shranjeno v:

Bibliografske podrobnosti
izdano v:	J Hematol Oncol
Main Authors:	Gu, Fei-fei, Zhang, Yong, Liu, Yang-yang, Hong, Xiao-hua, Liang, Jin-yan, Tong, Fan, Yang, Jing-song, Liu, Li
Format:	Artigo
Jezik:	Inglês
Izdano:	BioMed Central 2016
Teme:	Letter to the Editor
Online dostop:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4974806/ https://ncbi.nlm.nih.gov/pubmed/27496196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0296-8
Oznake:	Označite Brez oznak, prvi označite!

Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy

Podobne knjige/članki